Compare AbCellera Biologics Inc (ABCL) vs Ishares Msci Brazil ETF (EWZ) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

EWZ, the iShares MSCI Brazil ETF, trades at $34.92, up 1.42% over 24 hours, with a bullish technical signal driven by moving averages. The ETF has gained approximately 11% year-to-date, supported by Brazil's monetary easing cycle and commodity strength. Recent news highlights potential as a 2026 sleeper trade if rate cuts proceed, with exposure to Brazilian equities trading at a forward P/E of 9.6x as of Seeking Alpha on 2026-05-05.

Outlook is positive due to asymmetric upside from rate cuts, election repricing, and commodity tailwinds, but risks include Brazil's economic volatility and dependency on Petrobras/Vale dividends. Investors face currency and political uncertainties, though institutional interest remains with new positions like Altfest's $4.72 million investment in Q4 2025 per Defense World on 2026-04-12.